X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Ampligen (Rintatolimod) is an intraperitoneally administered small molecule drug candidate, which is currently being evaluated in combination with pembrolizumab and cisplatin for the treatment of recurrent ovarian cancer.
Lead Product(s): Rintatolimod,Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist which is under phase 1/2 clinical development in combination with Imfinzi (durvalumab) for the treatment of pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist, small molecule drug candidate, which is being evaluated in phase 2 clinical trials for the treatment of Post-COVID conditions.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
Ampligen (rintatolimod) is a US-FDA approved TLR3 agonist. It is being evaluated in phase 2 clinical trials for the treatment of locally advanced pancreatic cancer.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist which is being evaluated under phase 1/2 clinical trials in combination with anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of late-stage pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2024
Details:
Ampligen (rintatolimod) is a TLR-3 agonist which is under phase 1/2 clinical development in combination with Imfinzi (durvalumab) for the treatment of pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity, being developed as a potential therapeutic for people with the Post-COVID condition of fatigue.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and is being evaluated in combination with Paclitaxel in Phase 1 Study for the treatment of people with early-stage triple negative breast cancer.
Lead Product(s): Rintatolimod,Celecoxib,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and evaluating as a potential therapeutic for people with post-COVID conditions.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and evaluating Phase 2 Study for the Treatment of people with post-COVID conditions.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amarex Clinical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and evaluating Phase 1b/2 Study Combination with Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity. It is currently being evaluated in many aspects of SARS-CoV-2/COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post COVID conditions.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Ampligen (rintatolimod) is an immuno-modulator being developed for globally important cancers, viral diseases and disorders of the immune system. It stimulates the innate immune system by binding to and activating TLR-3 receptors for broad-spectrum immune response.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
The research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancer.
Lead Product(s): Rintatolimod,Durvalumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2023
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity. It is currently being evaluated in many aspects of SARS-CoV-2/COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post COVID conditions.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
The data showed positive safety, tolerability and biological activity of a 13-day dosing regimen conducted in Q2 2021 for intranasal Ampligen® (rintatolimod) in healthy subjects.
Lead Product(s): Rintatolimod,Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has demonstrated in the clinic the potential for standalone efficacy in a number of solid tumors.
Lead Product(s): Rintatolimod,Interferon Alfa-2B,Paclitaxel
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity currently being evaluated for the treatment of globally important cancers, viral diseases and disorders of the immune system.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
In the AMP-516 study in people with ME/CFS, Ampligen (rintatolimod) has demonstrated an encouraging safety profile and was well tolerated, and data in post-COVID from the AMP-511 study shows a similar profile.
Lead Product(s): Rintatolimod
Therapeutic Area: Immunology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Ampligen (rintatolimod) is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
Lead Product(s): Rintatolimod,Interferon Alfa-2B,Celecoxib
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally advanced pancreatic cancer.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
The preliminary data from uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with an immuno-modulator Ampligen (rintatolimod).
Lead Product(s): Rintatolimod,Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC).
Lead Product(s): Rintatolimod,Interferon Alfa-2B,Celecoxib
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
Ampligen® (rintatolimod), is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.
Lead Product(s): Rintatolimod,Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
Ampligen (rintatolimod), anti-tumor potential is demonstrated with checkpoint blockade therapies in human clinical studies for the treatment of triple-negative breast cancer and advanced recurrent ovarian cancer.
Lead Product(s): Rintatolimod,Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Ampligen (rintatolimod) has demonstrated in clinic potential for standalone efficacy in a number of solid tumors, it also has shown success in increasing survival rates and efficacy in treatment of animal tumors when used in combination with checkpoint blockade therapies.
Lead Product(s): Rintatolimod,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
The data, from a small number of subjects, is extremely impressive for four out of six Ampligen plus pembrolizumab patients; three demonstrated disease stabilization and one showed a significant and dramatic rapid destruction of the tumor and metastasis.
Lead Product(s): Rintatolimod,Celecoxib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
Primary endpoint of the study was met for Ampligen (rintatolimod), selective TLR3 ligand, evidenced by increased CD8a expression post-treatment (p=0.046), as a component of treatment for colorectal cancer metastatic to the liver.
Lead Product(s): Rintatolimod,Celecoxib,Recombinant Interferon Alfa-2b
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Roswell Park Comprehensive Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
Results from the study demonstrated Ampligen decreased the proliferation and migration ability of CFPAC-1 cells. In addition, it decreased the proliferation of MIAPaCa-2 cells and the migration of PANC-1 cells.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Ampligen (rintatolimod) sterile solution is indicated for the treatment of severely debilitated patients with chronic fatigue syndrome (cfs) who have been diagnosed for longer than one year.
Lead Product(s): Rintatolimod,Interferon Alfa-2B,Paclitaxel
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
Data seen to date indicates that Ampligen® (rintatolimod), AIM’s dsRNA product candidate could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
By combining three drugs – Ampligen and pembrolizumab, which are both immune therapies, with cisplatin, a chemotherapy – evidence of increased biomarkers associated with T cell chemotaxis and cytolytic function has been seen.
Lead Product(s): Rintatolimod,Pembrolizumab,Cisplatin
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
Roswell Park Comprehensive Cancer Center will present findings from two ongoing clinical studies involving an AIM ImmunoTech Inc. drug candidate, Ampligen® (also known as rintatolimod), as well as CT105 and CT145.
Lead Product(s): Rintatolimod,Celecoxib,Pembrolizumab
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
Treatment with Ampligen (rintatolimod), developmental first-in-class drug of large macromolecular RNA molecule, following FOLFIRINOX was associated with improved survival rates in pancreatic cancer patients compared to matched controls of patients who did not receive Ampligen.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
AIM ImmunoTech has submitted an application to USFDA studied Ampligen (Rintatolimod), a potential infusion treatment for post-Covid-19 cognitive dysfunction.
Lead Product(s): Rintatolimod,Influenza Vaccine Live
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. Primary objective of comparing the efficacy of Ampligen when added to SOC versus SOC alone for pancreatic carcinoma recently treated with FOLFIRINOX chemotherapy regimen.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2), which could help establish Ampligen as a potential prophylaxis against future viral variants and COVID-19.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
Details:
Rintatolimod (Ampligen®) is a mismatched, double-stranded RNA molecule with immunomodulatory and antiviral properties, currently under development for locally advanced or metastatic late-stage pancreatic cancer.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2021
Details:
HCT will allow AIM to expedite the development process for Ampligen by ensuring full exposure of both the control group and the Ampligen group, so as to assess whether there is a prophylactic effect.
Lead Product(s): Rintatolimod,Influenza Vaccine Live
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: hVIVO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 30, 2021
Details:
Ampligen has demonstrated clear activity in prior SARS-CoV-1 virus animal experiments for COVID-19. Intranasal Ampligen conferred a boost to homologous reactivity when used as an influenza vaccine adjuvant.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
Ampligen as both intranasal and an intravenous therapy for Post-COVID-19 Cognitive Dysfunction (PCCD). Exploratory endpoints to gather data supporting the Ampligen-enhanced immunity to wide range of RNA respiratory viruses, such as influenza, Rhinoviruses and SARS-CoV-2.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2021
Details:
Human Challenge Trial (HCT) to test Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2) against infectious, viral respiratory diseases and future pandemics.
Lead Product(s): Rintatolimod,Influenza Vaccine Live
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2021
Details:
The study will be a Phase 2, two-arm, randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the efficacy and safety of Ampligen in patients experiencing PCCD.
Lead Product(s): Rintatolimod
Therapeutic Area: Psychiatry/Psychology Product Name: Ampligen
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
A successful Phase 2 study could also establish Ampligen as a potential prophlyaxis against future viral variants and future novel respiratory viruses for which there are no current therapies.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2021
Details:
AIM ImmunoTech has reported that no serious adverse events were observed in Cohort 1 of a Phase I AMP-COV-100 (CHDR2049) clinical study of its drug Ampligen as an intranasal therapy for Covid-19.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2021
Details:
AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
AIM ImmunoTech has received formal notification from the European Commission (EC) approving the company’s Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer.
Lead Product(s): Rintatolimod
Therapeutic Area: Oncology Product Name: Ampligen
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
CHDR, will conduct and manage the proposed clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aim ImmunoTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 29, 2021
Details:
AIM ImmunoTech has dosed its first Covid-19 ‘long hauler’ patient in the active AMP-511 Expanded Access Program (EAP) with the Ampligen (rintatolimod) drug for the treatment of post-Covid-19 infection chronic fatigue-like symptoms.
Lead Product(s): Rintatolimod
Therapeutic Area: Immunology Product Name: Ampligen
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
Details:
AIM researchers found that the TLR3 agonist Ampligen substantially improved physical performance in a subset of ME/CFS patients. The data were published in PLOS ONE.
Lead Product(s): Rintatolimod
Therapeutic Area: Immunology Product Name: Ampligen
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
